Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients
ENTX•Planned Phase 3 study
Entera said it plans a single Phase 3 trial in about 750 postmenopausal women to support a potential NDA filing.
Phase 2 post-hoc analysis of EB613
Entera Bio said new post-hoc Phase 2 analyses of EB613, an oral bone-forming osteoporosis tablet, have been selected for presentation at ASBMR 2026.
The company said the results were not previously disclosed and are scheduled for presentation October 9-12, 2026, including a plenary poster session.
According to Entera, the analysis indicates stronger bone-building effects in postmenopausal women with more severe osteoporosis and higher fracture risk.
